Clearbridge BSA was formed in 2012 upon Clearbridge Accelerator's successful appointment as a recipient of SPRING Singapore's Biomedical Sciences Accelerator programme. Under the programme, Clearbridge BSA manages a SGD 40 million fund, of which SGD 20 million is provided by SPRING SEEDS Capital on a 1:1 co-financing basis. Clearbridge BSA will be responsible for identifying, evaluating, financing and managing Singapore-based medical technology start-up companies demonstrating high potential.
Clearbridge BSAs investment committee consists of Johnson Chen, Managing Partner of Clearbridge Accelerator, Dr. Lim Jui, CEO, Nanyang Innovation and Enterprise Office at NTU, and Damien Lim, General Partner BioVeda Capital.